Both Phase 3 trials met all primary and secondary endpoints with high statistical significance in patients with moderate-to-severe plaque ...

Biotech stock Alumis catapulted on Tuesday after the company unveiled promising results that could help it compete against ...

Alumis Inc. ( ($ALMS) ) just unveiled an announcement. On January 6, 2026, Alumis reported positive topline Phase 3 results from its ONWARD1 and ...

Both drugs also showed in their phase 3 trials that they were superior to Amgen's oral PDE4 inhibitor Otezla (apremilast), ...

Shares of Alumis gained on plans to share topline data from a Phase 3 trial evaluating envudeucitinib to treat moderate-to-severe plaque psoriasis. The stock rose 8.9% to $9.05 in after-hours trading ...

Investing.com -- Alumis Inc. (NASDAQ:ALMS) stock surged 60% Tuesday after the company reported positive Phase 3 trial results for its psoriasis drug envudeucitinib, showing superior skin clearance ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

NB-UVB phototherapy may restore adalimumab efficacy in chronic plaque psoriasis after treatment failure. Learn more about ...

The XGBoost model predicts hyperglycemia risk in psoriasis patients with high accuracy, achieving an AUC of 0.821 in the training set. A web-based calculator was developed to facilitate personalized ...

Psoriasis is a lifelong condition that comes and goes in flares, and the key to managing it is the right treatment. Your dermatologist will help you find a therapy based on: How bad your symptoms are ...

Search online for psoriasis images, and you'll mostly find photos of white people. But that doesn’t reflect the reality of this skin condition. People with dark skin get psoriasis, too. Fewer African ...